+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06102057

Phase II Study of FDG-PET Guided Small Volume Accelerated Chemoradiotherapy and Durvalumab Immunotherapy in Adults with Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer

Led by TheraOp · Updated on 2025-12-17

110

Participants Needed

11

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for patients with locally advanced, unresectable Stage III non-small cell lung cancer NSCLC. This randomized, controlled phase II trial compares two radiotherapy methods combined with chemotherapy to assess completion rates and other outcomes. After chemoradiotherapy, patients receiving stable or improved disease will get consolidation immunotherapy with durvalumab for up to 12 months or until disease progression or other stopping criteria. Participants are assigned to one of two groups one receives standard FDG-PET-based radiotherapy with concurrent chemotherapy, and the other receives FDG-PET-based small volume accelerated radiotherapy with concurrent chemotherapy. Following initial treatment, those with complete response, partial response, or stable disease continue with durvalumab immunotherapy. The study includes a safety follow-up period of about three months after durvalumab therapy ends, then survival follow-up until two years after the last patient starts durvalumab. During the study, participants undergo FDG-PET CT scans, pulmonary function tests, and laboratory tests to monitor health and treatment effects. Researchers track treatment completion rates, adverse events, disease progression, symptom changes, quality of life, and survival outcomes over several months to years. The study also assesses radiotherapy quality and requires patients to comply with scheduled visits and testing throughout the treatment and follow-up periods.

CONDITIONS

Brief Title

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Research Team

B

Bernhard Remes, Dr.

S

Sascha Herzer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here